Oncology Institute Inc (TOI) has a current Price-to-Book (P/B) ratio of -29.17. Compared to its 3-year average P/B ratio of -0.31, the current P/B ratio is approximately 9237.23% higher. Relative to its 5-year average P/B ratio of 0.57, the current P/B ratio is about -5181.67% higher. Oncology Institute Inc (TOI) has a Forward Free Cash Flow (FCF) yield of approximately -7.62%. Compared to its 3-year average FCF yield of -83.87%, the current FCF yield is approximately -90.91% lower. Relative to its 5-year average FCF yield of -64.97%, the current FCF yield is about -88.26% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TOI competitors is 1.06, providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI.O) exhibits a P/S ratio of 0.61, which is -42.25% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TOI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TOI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TOI currently overvalued or undervalued?

What is Oncology Institute Inc (TOI) fair value?

TOI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Oncology Institute Inc (TOI) is between 2.54 to 3.84 according to relative valuation method.

How does TOI's valuation metrics compare to the industry average?

The average P/S ratio for TOI's competitors is 1.06, providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI) exhibits a P/S ratio of 0.61, which is -42.25% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.

What is the current P/B ratio for Oncology Institute Inc (TOI) as of Mar 02 2026?

As of Mar 02 2026, Oncology Institute Inc (TOI) has a P/B ratio of -29.17. This indicates that the market values TOI at -29.17 times its book value.

What is the current FCF Yield for Oncology Institute Inc (TOI) as of Mar 02 2026?

As of Mar 02 2026, Oncology Institute Inc (TOI) has a FCF Yield of -7.62%. This means that for every dollar of Oncology Institute Inc's market capitalization, the company generates -7.62 cents in free cash flow.

What is the current Forward P/E ratio for Oncology Institute Inc (TOI) as of Mar 02 2026?

As of Mar 02 2026, Oncology Institute Inc (TOI) has a Forward P/E ratio of -10.49. This means the market is willing to pay $-10.49 for every dollar of Oncology Institute Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Oncology Institute Inc (TOI) as of Mar 02 2026?

As of Mar 02 2026, Oncology Institute Inc (TOI) has a Forward P/S ratio of 0.61. This means the market is valuing TOI at $0.61 for every dollar of expected revenue over the next 12 months.

TOI Valuation